Mort de Raphael Mechoulam, le « père de la recherche sur le cannabis » en Israël Le scientifique a mené des recherches pionnières sur le cannabis, dont les résultats ont permis à cette substance de passer de la contre-culture au courant dominant Par ANDREW SILOW-CARROLL Times of Israël, 12 mars 2023, 16:20 Le professeur Raphael Mechoulam dans son laboratoire du campus Ein Kerem de l’Université hébraïque, le 1er septembre 2016. (Crédit : Melanie Lidman/Times of Israel) JTA — Au début des années 1960, un scientifique d’origine bulgare nommé Raphael Mechoulam est surpris avec cinq kilogrammes de ce qu’il qualifie « de magnifique haschisch libanais de contrebande » [...]
Lire la suiteNegative experiences of patients using medicinal cannabis : A systematic review of qualitative studies Or Gliksberg, P Talma Kushnir, Sharon R. Sznitman, Shaul Lev-Ran, Silviu Brill, Ben H. Amit, Daniel Feingold PhD, Journal of Clinical Nursing, 2023, 1-12. doi : 10.1111/jocn.16653 Abstract Aims and Objectives : In this study, we systematically reviewed qualitative studies concerning patients' experience with medicinal cannabis (MC) use, to gain insight into the negative effects of MC. Background : Over the past decades, the use of MC for therapeutic purposes has increased. However, there is conflicting and insufficient data on possible negative physiological and psychological effects of MC treatment. Design : A systematic review was [...]
Lire la suiteMort du chercheur Raphael Mechoulam, chantre du chanvre médical par Charles Delouche-Bertolasi Libération,13 mars 2023 Pionnier de l’utilisation médicale du cannabis, le scientifique israélien est mort le 9 mars à Jérusalem, à l’âge de 92 ans. Entre autres découvertes, il est celui qui a réussi en 1964 à isoler le THC, principe actif du cannabis. Raphael Mechoulam, lors d'une conférence à Tel Aviv, en mars 2016. (JACK GUEZ/AFP) Depuis quelques jours, certains fumeurs de joints dédient leurs exhalaisons à un homme, qui vient de s’éteindre en Israël à l’âge de 92 ans : le docteur Raphael Mechoulam, chimiste et scientifique, chercheur pionnier à l’origine de la découverte du delta-9 [...]
Lire la suiteThe Rapid Rise in Investment in Psychedelics— Cart Before the Horse Joshua PHELPS, Ravi N. SHAH, Jeffrey A. LIEBERMAN, JAMA Psychiatry, 2022, 79, (3), 189-190. Doi : 10.1001/jamapsychiatry.2021.3972 Anticipating a renaissance, many psychedelic medicine companies have conducted initial public offerings, where in private companies first issue news hares of stock for sale to the public, making the companies publicly traded entities.1 As of this writing, there are more than 50 publicly traded companies related to the development or administration of psychedelic like drugs in the US, with at least 3 valued at more than $1 billion. The market for psychedelic substances is projected to [...]
Lire la suiteConducting Qualitative Research With Psychedelic Psychopharmacologists : Challenges of Co-Production in an Era of Interdisciplinarity Tehseen Noorani SAGE Research Methods Cases Part 2, March 3, 2017, 1-14 Doi : 10.4135/9781526404862 Abstract From 2013 to 2015, I worked as a postdoctoral research fellow with a team of pharmacologists experimenting with psilocybin, an illegal psychoactive compound found in psychedelic mushrooms. The team had conducted an open-label clinical trial with long-term cigarette smokers, using psilocybin-assisted psychotherapy to help them quit. The smoking outcomes were very promising, occurring alongside many other profound positive life-changes. The team wanted to investigate further the mechanisms of change by which the study led [...]
Lire la suiteDirect comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects Friederike Holze, Laura Ley, Felix Müller, Anna M. Becker, Isabelle Straumann, Patrick Vizeli, Sebastian Silva Kuehne, Marc A. Roder, Urs Duthaler, Karolina E. Kolaczynska, Nimmy Varghese, Anne Eckert and Matthias E. Liechti Neuropsychopharmacology, 2022, 1-8. Doi : 10.1038/s41386-022-01297-2 Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double blind, randomized, placebo-controlled, [...]
Lire la suiteCannabis is indigenous to Europe and cultivation began during the Copper or Bronze age: a probabilistic synthesis of fossil pollen studies John M. McPartland · Geoffrey W. Guy · William Hegman Vegetation History and Archaeobotany, 2018, 27, 635–648 Doi : 10.1007/s00334-018-0678-7 Abstract Conventional wisdom states Cannabis sativa originated in Asia and its dispersal to Europe depended upon human transport. Various Neolithic or Bronze age groups have been named as pioneer cultivators. These theses were tested by examining fossil pollen studies (FPSs), obtained from the European Pollen Database. Many FPSs report Cannabis or Humulus (C/H) with collective names (e.g. Cannabis/Humulus or Cannabaceae). To dissect these aggregate [...]
Lire la suiteAssessing the risk-benefit profile of classical psychedelics : a clinical review of second-wave psychedelic research David Bender & David J. Hellerstein Psychopharmacology (Berl), 2022. Doi : 10.1007/s00213-021-06049-6 Abstract Rationale : A broad reassessment of the potential benefits of psychedelic drugs has led to the initiation of multiple major clinical trials in an effort to advance their status to become FDA-approved medications, as well as local legislative efforts to legalize or decriminalize their use. Objectives : To use recently published data to assess potential risks and benefits of psychedelic drugs as therapeutics, as well as to synthesize what is currently known in order [...]
Lire la suiteAssessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c‑Fos and NeuN expression in the hypothalamus of rats Eric Murillo‑Rodríguez, Diana Millán‑Aldaco, Gloria Arankowsky‑Sandoval, Tetsuya Yamamoto, Roger G. Pertwee, Linda Parker and Raphael Mechoulam Abstract Background : Cannabidiol (CBD), the non-psychotropic compound from Cannabis sativa, shows positive results on controlling several health disturbances; however, comparable data regarding additional chemical from C. sativa, such as cannabidiolic acid (CBDA), is scarce due to its instability. To address this limitation, a stable CBDA analogue, CBDA methyl ester (HU-580), was synthetized and showed CBDA-like effects. Recently, we described that HU-580 increased [...]
Lire la suitePsychedelic psychiatry’s brave new world. Nutt, D., Erritzoe, D., & Carhart-Harris, R. Cell, 2020, 181, (1), 24-28. Doi : 10.1016/j.cell.2020.03.020 After a legally mandated, decades-long global arrest of research on psychedelic drugs, investiga- tion of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction. Introduction—Why the Psychedelic Revolution in Psychiatry? Research leading to the discovery of new pharmacological treatments for psychiat- ric disorders has been painfully slow. With a few exceptions, including the use of orexin [...]
Lire la suite